Comparative Pharmacology
Head-to-head clinical analysis: AUROVELA 24 FE versus NORINYL 1 80 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUROVELA 24 FE versus NORINYL 1 80 21 DAY.
AUROVELA 24 FE vs NORINYL 1+80 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive. Norethindrone acetate suppresses gonadotropin release (FSH and LH) via progestogenic activity, inhibiting ovulation. Ethinyl estradiol provides negative feedback on hypothalamic-pituitary axis, further suppressing gonadotropins and stabilizing endometrium.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
One tablet (0.10 mg ethinyl estradiol / 1.0 mg norethindrone acetate) orally once daily for 24 days, followed by 4 days of ferrous fumarate 75 mg tablets (placebo). Administer at the same time each day without interruption.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
None Documented
None Documented
Norethindrone: 7-8 hours; Ethinyl estradiol: 13-16 hours. Steady-state achieved within 5 days.
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Norethindrone: ~40% renal, ~60% fecal; Ethinyl estradiol: ~40% renal, ~60% fecal as glucuronide and sulfate conjugates.
Renal (40-60% as metabolites), fecal (20-30%)
Category C
Category C
Oral Contraceptive
Oral Contraceptive